2018 Letter to Shareholders

To the Shareholders of Vitality Biopharma, Inc., I wrote to you less than two years ago describing our discovery that a Stevia plant enzyme could be used to create a new class of cannabinoid compounds.  We quickly recognized the value, seeing that these novel molecules, known as cannabosides, might enable targeted delivery and provide therapeutic...

Shareholder Letter

Dear Shareholder: As an early-stage company, we’ve made notable progress over the last 2-3 years, and throughout it all we’ve been looking for a catalyst that will take our company to the next level. In a fortuitous turn of events, and as part of our ongoing R&D efforts, we have made significant discoveries that we...